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Abstract. For bladder cancer, intravesical chemo/immunotherapy is widely used as adjuvant therapies
after surgical transurethal resection, while systemic therapy is typically reserved for higher stage, muscle-
invading, or metastatic diseases. The goal of intravesical therapy is to eradicate existing or residual
tumors through direct cytoablation or immunostimulation. The unique properties of the urinary bladder
render it a fertile ground for evaluating additional novel experimental approaches to regional therapy,
including iontophoresis/electrophoresis, local hyperthermia, co-administration of permeation enhancers,
bioadhesive carriers, magnetic-targeted particles and gene therapy. Furthermore, due to its unique
anatomical properties, the drug concentration-time profiles in various layers of bladder tissues during and
after intravesical therapy can be described by mathematical models comprised of drug disposition and
transport kinetic parameters. The drug delivery data, in turn, can be combined with the effective drug
exposure to infer treatment efficacy and thereby assists the selection of optimal regimens. To our
knowledge, intravesical therapy of bladder cancer represents the first example where computational
pharmacological approach was used to design, and successfully predicted the outcome of, a randomized
phase III trial (using mitomycin C). This review summarizes the pharmacological principles and the
current status of intravesical therapy, and the application of computation to optimize the drug delivery to
target sites and the treatment efficacy.
KEY WORDS: bladder cancer; computational modeling; intravesical therapy; pharmacokinetic/
pharmacodynamic; regional therapy.
INTRODUCTION
Bladder cancer is the fifth most common cancer in the
United States, with an estimated 67,160 newly diagnosed
cases and 13,750 deaths in the United States in 2007. The
5-year survival rate is 82% for all stages combined (1). The
standard of treatment for patients with superficial bladder
cancer is surgical transurethal resection (TUR) of tumors,
with an 80% early success rate. However, nearly 70% of these
patients will develop tumor recurrence, with 25% showing
progression to muscle-invading disease, within 5 years with
TUR (2). Intravesical chemotherapy and immunotherapy are
widely used as adjuvant therapies after TUR, to prevent
recurrence and progression of superficial disease. Systemic
therapy is typically reserved for higher stage, muscle-invading,
or metastatic diseases.
The urinary bladder is an ideal organ for regional therapy.
The urethra provides easy access of therapeutic agents to the
urinary bladder. The presence of the specialized asymmetric
unit membrane on the urothelium serves as a barrier and limits
the absorption of molecules or particulates into the systemic
circulation. For most small molecule drugs, less than 5% of the
dose is absorbed into the systemic circulation (3–5). The
rationale for intravesical therapy is to maximize the exposure
of tumors located in the bladder cavity to therapeutics agents
while limiting the systemic exposure and thereby limiting the
host toxicities; the primary goal is to eradicate existing or
residual tumors through direct cytoablation or immunostimu-
lation. The unique properties of the urinary bladder render it
a fertile ground for evaluating novel experimental approaches
to regional therapy, including iontophoresis/electrophoresis,
local hyperthermia, co-administration of permeation
enhancers, bioadhesive carriers, magnetic-targeted particles
and gene therapy.
This review consists of five parts. Part I summarizes the
current status of intravesical treatments of bladder cancer.
Part II discusses the drug disposition in bladder tissues during
intravesical therapy. Part III discusses the application of
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computation to optimize intravesical treatments. Part IV sum-
marizes the experimental approaches under preclinical and
clinical evaluation. Part V provides the general perspectives.
PART I. CURRENT STATUS OF INTRAVESICAL
TREATMENTS
Immunomodulators. Bacille Calmette-Guérin (BCG) is
the most adopted first-line immunotherapeutic and is the most
effective treatment for prophylaxis and treatment of carcinoma
in situ (CIS). Phase I and II trials have shown that other
immunoregulators such as interferons (IFN) (6–8), interleukin-
2 (IL-2) (9–11), interleukin-12 (IL-12) (12,13), tumor necrosis
factor (TNF) (14–16), keyhole limpet hemocyanin (KLH) (17,
18) and rubratin (19,20) have activity in BCG-refractory
patients, albeit with low durable remissions (<20%).
Chemotherapy. Multiple chemotherapeutic agents, such
as mitomycin C (MMC) (21–25), doxorubicin (26–28),
epirubicin (29–32), thiotepa (33,34), ethoglucid (35–37),
valrubicin (38–40), cisplatin (41–43), gemcitabine (44–46),
suramin (47,48) or their combinations (49–52) have been
evaluated in patients; meta-analyses did not show apparent
superiority of a particular treatment. The addition of intra-
vesical chemotherapy to TUR yields, on average, a further
reduction of recurrence by 14–17%, but has limited benefits
against disease progression (53).
BCG vs chemotherapy. Compared to several chemother-
apeutic agents (thiotepa, epirubicin and doxorubicin), BCG is
more effective in preventing tumor recurrence (14–47% lower
recurrence rate) and disease progression (54). In patients with
stage Ta or T1 carcinoma, BCG showed a lower recurrence
rate (38.6% versus 46.4%) and lower disease progression
(34% lower), compared to standard albeit suboptimal MMC
treatments (i.e., no pharmacological interventions to improve
the MMC delivery to tumor cells, see Part III) (55). Patients
who failed BCG and desired avoiding radical cystectomy
have been treated with intravesical IFN-α (56–59), valrubicin
(60) or gemcitabine (61,62) with some limited success.
PART II. DRUG DISPOSITION DURING
INTRAVESICAL THERAPY
Drug disposition in the bladder during intravesical
therapy is affected by several attributes, i.e., physicochemical
properties of the drug (molecular weight, hydrophilicity or
lipophilicity, water/lipid partition coefficient), urine volume
and pH, patient hydration status, and integrity of urothelium.
Our laboratory has provided the first pharmacokinetic models
to describe drug disposition in urine and bladder tissues. These
models enable the prediction of changes in drug concentration
in different parts of bladder wall as a function of physiological,
pathological or pharmacological parameters (63).
The first set of equations describes the urine pharmaco-
kinetics during treatment:
Cu ¼ DoseVu e
 KaþKdð Þt ð1Þ
Vu ¼ V0 þK0t þ Vres ð2Þ
where Cu is the urine drug concentration at time t, Vu is the
volume of the urine, Ka is the first order rate constant
describing drug absorption into the systemic circulation, Kd is
the hybridized first order rate constant describing degrada-
tion, metabolism, and tissue binding, Vo is the dosing volume,
K0 is the zero order rate constant describing urine production,
and Vres is the post-catheterization residual urine volume.
The urine pharmacokinetic model provides the tool to
depict changes in urine drug concentrations due to changes in
physiological parameters that can vary from patient to patient
(e.g., residual urine volume, urine pH, urine production rate)
and changes in drug-related parameters (e.g., dose, dosing
volume, degradation in acidic or basic environment). It is
noted that most of the small molecule drugs used in intra-
vesical chemotherapy have pH-dependent stability, e.g.,
MMC is unstable in pH<5 or pH>8 (64, 65), thiotepa and
its active metabolite are unstable in acidic pH (<5) and stable
at alkaline pH (8.4) (66, 67), whereas doxorubicin is more
stable in acidic pH (5.4) than in alkaline pH (8.1) (68). pH
also affects the antitumor activity, e.g., MMC is more active at
acidic pH in monolayer cultures (but no pH dependent-effect
in 3-dimensional cultures) (69), epirubicin is more active at
alkaline pH (8.0) than at lower pH (6.0) (70). The urine
production rate and residual urine volume can be altered by
patients’ hydration status, e.g., dehydration for 6 hr decreased
the average volume of urine production from 209 to 143 ml,
which is further reduced to 103 ml by co-administering an
antidiuretic desmopressin (71).
For a drug-of-interest, the urine pharmacokinetic model
can be established by defining the values of the rate constants
in the equations. The values for the physiological parameters
in patients can be readily obtained from the literature. The
values for the drug-related parameters are either defined by
investigators (e.g., dose, dosing volume) or by measuring the
degradation rate in buffers with different pH values. Success-
ful development of the urine pharmacokinetic model for a
drug-of-interest would enable the prediction of the effects of
changing the various parameters on the urine drug concen-
trations and, because the urine concentration is the driving
force for delivering the drug to bladder tissues, on the drug
concentrations in the urothelium layer.
The second set of equations describes the drug transport
in bladder tissues, as a function of time and distance from the
urine compartment. For this purpose, the bladder wall is
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divided into two sections, the urothelium (mucosa) that is not
blood-perfused and the submucosal and muscle layers of the
bladder that contain blood vessels and lymphatics. Drug
transport from the urine compartment across the urothelium
(about 7–10 cell layer or 200 μm thick in man (72)) is depicted
by diffusion across a single homogeneous diffusion barrier
and is described by Fick’s first law (Eq. 3). Drug transport
across the submucosa and superficial muscle (200–4,000 μm)
is described by the distributed model (Eq. 4) (5,63,73,74). The
distributed model integrates drug diffusion through a porous
structure and drug removal/absorption through the blood
vessels.
Urothelium (0–200 μm):
Cdepth ¼ Cu  Cu  Curo200  depth ð3Þ
Submucosa/superficial muscle layer (200–4,000 μm):
Cdepth ¼ Curo  Cbð Þ  e
0:693
W1=2
 depth200ð Þ þ Cb ð4Þ
In the urothelium, Cu is the concentration of unionized
drug in the bladder cavity and is the link between the urine
and tissue pharmacokinetics. Curo is the concentration at the
interface between the urothelium and the submucosa, or
about 200 μm away from the surface of the urothelium lining.
Cdepth is the concentration at a particular tissue depth. In the
urothelium, Cdepth declines linearly with increasing depth
because diffusion is not dependent on the depth. In the
submucosa and superficial muscle layer, Cdepth is determined
by Curo, the plasma drug concentration Cb in blood vessels,
the tissue depth away from the urothelium and the half-width
W1/2. The latter is the thickness of tissue over which the drug
concentration declines by 50%. Because the number of
vessels encountered by the drug molecule increases with
increasing tissue depth (assumed to be evenly distributed),
the decline of Cdepth in submucosa and superficial muscle
layers is first order with respect to tissue depth.
We have experimentally determined the pharmacokinet-
ic model parameters for several drugs, i.e., MMC, doxorubi-
cin, 5-fluorouridine and paclitaxel. The first three less
lipophilic drugs show comparable penetration across the
urothelium with a Curo/Cu ratio of 0.02 to 0.03, whereas the
more lipophilic paclitaxel shows a significantly higher Curo/Cu
ratio of about 0.5. These findings, together with the earlier
finding of the extensive systemic absorption of the lipophilic
small molecule thiotepa (MW, 189 Da) (75), indicate that
lipophilicity is a key determinant of drug penetration across the
urothelium. Another consideration is systemic absorption; the
absorption ofMMC, doxorubicin, 5-fluorouridine and paclitaxel
after intravesical therapy is consistently lower compared to
thiotepa (<5% vs 20%) (3,4,73,76). We infer that an ideal drug
for intravesical therapy would be a lipophilic compound that
can readily penetrate the urothelium and remain localized in
bladder tissue (as opposed to being rapidly absorbed into the
systemic circulation). Note that the model for drug transport
across the urothelium enables the computation of effects of
altering the urothelium barrier function (e.g., compromised
urothelium due to surgery or treatment with surfactant or
absorption enhancers).
A second generation bladder tissue kinetic model was
recently described (77). The major modification is the
arbitrary subdivision of the bladder wall into 30 serially
interconnected compartments (4 within the urothelium and
26 within the deeper, capillary-perfused tissues). This model
was used to generate simulations of the concentration-depth
profiles of a hydrophilic drug pipemidic acid (PPA), for the
purpose of studying its systemic absorption rate, and the
effects of co-administering bioadhesive permeation enhancers
(chitosan and polycarpophil). The model parameters such as
tissue partition coefficient and diffusion rate constants were
obtained using in vitro drug transport data generated using
the isolated porcine bladder. The mathematical expansion of
the bladder tissues from 2 compartments into 30 compart-
ments enables the inclusion of inter-compartmental drug
transfer and drug absorption from each sub-compartment
(e.g., different transport rates at different tissue locations)
and thereby enhances the data fitting capability. It is noted,
however, the anatomical and physiological relevance of the 30
sub-compartments is unclear and the model performance
under in vivo conditions cannot be ascertained because the
model parameters were obtained under in vitro conditions,
i.e., without intact blood perfusion.
The above urine and tissue pharmacokinetic models
provide the basis for computing drug delivery to the targeted,
tumor-residing sites in the bladder as a function of treatment
conditions (e.g., dose, drug concentration, volume of dosing
solution, patient hydration status, treatment duration), during
intravesical therapy. Integration of drug delivery with phar-
macodynamic data such as the effective drug concentrations
in preclinical models provides a means to rational design of
intravesical treatments (see Part III).
PART III. APPLICATION OF COMPUTATIONAL
MODELING TO OPTIMIZE INTRAVESICAL
TREATMENTS
Response of a patient to a treatment is largely deter-
mined by whether his/her tumor cells are sensitive to the
selected chemotherapy and whether sufficient drug is deliv-
ered to tumor cells. Tumor sensitivity is a biological/genetic
property that cannot be readily controlled or manipulated.
On the other hand, as discussed in Part II, the delivery of a
therapeutic agent to tumor cells located in different parts of
bladder wall can be depicted as mathematical relationships
with controllable variables such as dose, volume of dosing
solution, urine production rate during treatment, residual
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urine volume at the time of dose instillation, and urine pH.
Drug concentration in the urine compartment is directly
affected by the first four variables (e.g., a lower dose or a
larger urine volume diminishes the drug concentration),
whereas the pH affects the drug stability and thereby
indirectly determines the concentration of the intact drug.
The following example demonstrates the application of
computational modeling to clinical trial design (please see
reference (63) for a more detailed discussion). First, we used
the urine pharmacokinetic model described in Equations 1 to
4 to evaluate how changes in the variables or treatment
conditions alter the drug delivery (63). The simulated drug
amounts, equivalent to (concentration) x (treatment time)
product or CxT, were then compared to the drug concen-
trations found active in patient bladder tumors (n>60), in
order to determine the fraction of patients likely to receive
sufficient drug amount to produce a therapeutically meaning-
ful response under various treatment conditions. Computa-
tion was used to evaluate seven changes in treatment
conditions, including increasing the dose from 20 to 40 mg
or to 60 mg, decreasing the dosing volume from 40 to 20 ml,
increasing instillation time from 120 to 240 minutes, decreas-
ing urine production rate from 1.48 to 0.63 ml/min, reducing
residual volume from 32.4 ml to 0 ml and increasing pH from
5 to 7. The simulations predicted that changes of the above
parameters would affect the treatment outcome in the
following rank order: dose > urine residual volume > urine
production rate > dosing volume > urine pH > instillation
time.
The three major findings of the computer simulation
results are as follows. (a) Changing one parameter at a time
would yield small incremental improvements (i.e., <8%
higher 13-month recurrence free rate) such that at least 450
patients would be required to demonstrate the benefit of
changing a single individual treatment parameter. This
finding suggests that the inconclusive results for the earlier
trials that attempted to evaluate the benefits of changing
various individual treatment parameters were likely due to
inadequate patient sample size. (b) In contrast, simultaneous
changes in five treatment parameters (see below) would
increase the 13-month recurrence rate by 18–20%, a differ-
ence that is large enough to be detected with a relatively
small number of patients (230 patients showing 116 events).
(c) The simulation results further showed that two additional
changes in treatment parameters (using the maximally
tolerated dose of 60 mg or increasing the treatment time
from 2 to 4 hr) would not produce additional benefits.
The computer simulation results were used to synthesize an
optimized MMC treatment protocol that was subsequently
tested in a multi-center, two-arm phase III clinical trial (78). In
this trial, superficial bladder cancer patients with histologically
proven transitional cell carcinoma (Ta, T1, CIS) and at high
risk for recurrence were randomized to optimized or standard
treatment arms. Patients in the optimized arm received 40-mg
dose of MMC, with pharmacological manipulations to maxi-
mize the drug delivery (ultrasound-guided bladder emptying,
voluntary dehydration, urine alkalinization by oral sodium
bicarbonate). In the standard arm, patients received a 20-mg
dose and 20 ml dosing volume without manipulations. All
patients received intravesical treatments weekly for 6 weeks.
The primary endpoint was time to recurrence and the
secondary endpoint was recurrence-free rate. The results
showed that in evaluable patients, the median time to recur-
rence was 29.1 months in the optimized arm, significantly higher
than that in standard arm (11.8 months) (p<0.001). The
projected 5-year recurrence-free rate with amedian 11.7 months
follow-up was 42.6% in optimized arm and 23.5% in standard
arm, or a 19.1% increase. The extent of improvement is identical
to the simulated prediction (18–20% increase). To our knowl-
edge, this is the first efficacy trial designed based on computa-
tional results that shows good agreement between the model-
prediction and observed results.
PART IV. EXPERIMENTAL APPROACHES
Various experimental approaches in two general catego-
ries have been evaluated. Approaches in the first category
share a common theme of improving the total drug exposure,
by enhancing the delivery of agents to bladder tissues (e.g.,
using permeation enhancers, iontophoresis/electrophoresis,
hyperthermia, disrupting the extracellular matrix), prolonging
the exposure (e.g., using bioadhesive), or enhancing cell
membrane permeability (intravesical hyperthermia). The
second category is gene therapy, with the goal of either
correcting the mutated and malfunctioned genes responsible
for tumor formation and progression or as a means to deliver
intrinsic or extrinsic signals for cell destruction.
Permeation enhancers. Approaches to enhance urothelium
permeability or drug transport in extracellular matrix include
chemical and physical methods, as follows.
The chemical methods use permeation enhancers such as
dimethyl sulfoxide (DMSO), which has been used to treat
interstitial cystitis (79). Co-administration of DMSO (10–
50%) promoted the penetration of water-soluble drugs (e.g.,
cisplatin, pirarubicin, doxorubicin) (80–82) and a lipophilic
drug paclitaxel (83) across the urothelium in dogs or rats.
However, DMSO also promoted the urine production rate
and the absorption of paclitaxel from bladder tissues into
systemic circulation, thereby partially negating the benefits of
improved drug partition into bladder tissues (83).
Other permeability enhancers have been evaluated. Chito-
san is a cationic polysaccharide that, by binding to the negative
charges on cell membrane, causes rearrangement of cellular
tight junctions and enhances paracellular drug transport. Poly-
carbophil is a mucoadhesive polyacrylic acid cross-linked with
divinyl glycol that, by chelating with extracellular calcium ions,
causes opening of cellular tight junctions. In isolated porcine
bladder in vitro, co-administration of chitosan (0.05% to 1% w/
v) or polycarbophil (1%w/v) promoted the tissue penetration of
moxifloxacin (pKa values of 6.4 and 9.5) or pipemidic acid (pKa
values 5.4 and 8.2) by 3- or 4-fold (84,85).
Hyaluronan or hyaluronic acid, a glycosaminoglycan, is a
major component of extracellular matrix. Hyaluronidase, an
enzyme that hydrolyzes the hyaluronan network, can be
safely administered to humans and has been approved for
treating vitreous hemorrhage (86,87). Co-administration of
hyaluronidase improves drug diffusion into bladder mucosa in
rats (88). In humans, hyaluronidase did not improve the
efficacy of cisplatin in 33 patients (89), but significantly
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reduced the disease recurrence in superficial bladder cancer
patients compared to MMC alone (7% in 43 patients versus
32% in 63 patients) without enhancing the systemic drug
absorption (90,91). Hyaluronidase has other interesting
properties; it acts as either a tumor suppressor or promoter
depending on the cell type and concentration (92,93). Low
concentration of hyaluroindase (14–40 milliunits/106 cells)
stimulated tumor growth whereas high concentration
(>100 milliunits/106 cells) induced apoptosis and inhibited
tumor formation. These properties indicate the need of
carefully fine-tuning the hyaluronidase treatment conditions.
Physical methods to disrupt the urothelium include
electromotive therapy (iontophoresis/electrophoresis) and hy-
perthermia. Both methods are under clinical evaluations.
Electromotive administration, by temporary breaching of the
urothelium, increases the transport of MMC across urothelium
in human bladders (six to nine times higher compared to MMC
alone) and absorption into the plasma (∼5 times higher peak
plasma concentration); the peak concentration was 43 ng/ml or
about 1/10 of the threshold toxic concentration of 400 ng/ml
(94, 95). An earlier study in 28 patients with superficial bladder
tumors suggests that adding electromotive administration to
intravesical MMC did not improve the complete response rate
at 10 weeks post-treatment (40% for electromotive MMC vs
41% for MMC alone), but improved he reduction in the
recurrence rate (from 60% to 33%) and the duration of disease-
free interval (from 10.5 to 14.5 months) (96). A more recent
three-arm study compared MMC alone, MMC plus electro-
motive administration, and BCG in 117 high risk patients. The
results show that, compared to MMC alone, electromotive
MMC significantly improved the recurrence-free rate (58% vs
31% at 6 months, p=0.012) and significantly prolonged the
median time to recurrence (35 vs 19.5 months, p=0.013) (97).
The combination of MMC and electromotive administration
produced similar benefits as BCG (64% recurrence-free at
6 months and median time to recurrence of 266 months, p>
0.05). Another recent randomized trial in 212 high risk patients
further demonstrated a greater efficacy for a combination of
BCG followed by MMC plus electromotive administration,
compared to single agent BCG (prolongation of disease-free
interval from 21 to 69 months, reduction of recurrence rate from
57.9 to 41.9%, reduction of progression rate from 21.9 to 9.3%,
decrease of overall death rate from all causes from 32.4 to
21.5% and decrease of disease-specific death rate from 16.2 to
5.6%) (98). These results compare favorably to the earlier data
that showed no benefits in combining MMC and BCG relative
to single agents (99–102).
Intravesical thermo-chemotherapy, combination of chemo-
therapy and localized hyperthermia, is under clinical evaluation.
Hyperthermia enhances the effects of chemotherapy on inhibi-
tion of DNA synthesis and DNA damage, increases cell
membrane permeability and alters intracellular drug trafficking
and distribution (103–105). Intravesical hyperthermia is deliv-
ered using a microwave applicator inserted inside the bladder
cavity, where the bladder wall temperature is maintained at 42–
45°C. The drug solution is recycled to avoid overheating. In
two single arm trials in intermediate-to-high risk patients, this
modality showed a recurrence-free rate of 91% after a mean
follow up of 289 days (n=22) (105), 86% at 1 year and 75% at
2 year (n=90) (106). A multi-center, randomized trial compar-
ing the combination of intravesical MMC plus hyperthermia
with MMC alone in superficial bladder cancer patients shows
that adding hyperthermia improved the recurrence-free rate at
24 months (n=83, 83% vs 43%, p=0.0002) (23).
Prolonging residence time. Intravesical therapy is usually
given over 2 hr, after which time the drug is drained from the
bladder. Sustained-retention delivery platforms such as bio-
adhesive microspheres or hydrogel systems can serve as drug
depots, thereby extending the drug exposure in the bladder
cavity beyond the voiding of urine. In a mouse bladder cancer
model, bioadhesive, paclitaxel-loaded poly (methylidene malo-
nate) microspheres were retained on bladder wall for more than
48 hr, and yielded survival advantage over a solution of paclitaxel
in 5% Tween 80 (9-week survival rate of 91% vs 58%) (107).
Similarly, a solution-state thermosensitive poly-(ethylene gly-
col)-poly (lactic acid-co-glycolic acid)-poly (ethylene glycol)
polymer, capable of transforming itself into hydrogel matrix at
body temperature (37°C), showed sustained drug release/
retention in rat bladders over multiple bladder voidings for up
to 24 hr (108). Ye et al reported a gelatin–doxorubicin complex
that released doxorubicin for up to12 days (109). None of the
above formulations have been evaluated in humans.
Magnetic targeting. Magnetic targeting uses a magnet
placed externally on the skin covering a predetermined site in
the bladder (typically where tumors reside) to localize drug-
containing magnetic particles in tumors, thereby providing
continuous exposure to high drug concentrations in tumors.
In swine bladders, administration of magnetic doxorubicin-
loaded microparticles (10 to 80 mg drug in 300–800 mg
magnetic particles) followed by 30-min of external magnetic
targeting yielded localization of microparticles in superficial
and deep tissue layers of the magnetic-targeted sites (primar-
ily in superficial submucosa) that were retained for at least
44 days (110).
Gene therapy. Gene therapy poses several theoretical
advantages over chemotherapy: (a) high selectivity for tumor
cells with mutated genes, (b) restore cell growth to normalcy
by correcting genetic defects rather than by killing cells, and
(c) avoiding the emergence of chemoresistance. Development
of gene therapy in bladder cancer has focused on modifying
the mutated urothelial cells and restoring normal functions of
tumor suppressor genes. A popular target is p53. Mutation of
p53 gene or loss of p53 functions leads to uncontrolled cell
growth (111). As p53 mutation is found in about 40% of
bladder cancer patients with advanced transitional carcinoma
(112), p53 gene therapy is an attractive therapeutic approach.
The two major types of gene delivery systems are viral
and nonviral vectors. Viral vectors include adenovirus and
vaccinia. The advantages of adenoviral vector include: (a) it is
not integrated into host chromosomes, (b) ease of obtaining
recombinant proteins and producing vectors in high titers,
and (c) high viability of host cells post-infection. Adenovirus
normally enters a cell via its membrane receptor, coxsackie/
adenovirus receptor (CAR) (113,114). The luminal surface of
the urothelium is coated with a glycosaminoglycans (GAG)
layer (115), which retards the adherence of adenoviral vectors
to CAR and the subsequent gene transfection (116). The
GAG layer can be disrupted by ethanol (117), surfactants
(e.g., dodecyl-beta-D-maltoside or sodium dodecyl sulfate)
(118), Syn3 (a synthetic polyamide) (119) and low concentra-
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tion of hydrochloric acid (60 mM). Hydrochloric acid was
able to promote the transfection efficiency of intravesical E.
Coli LacZ gene in adenoviral vector from 10% to 80% in rat
urothelial cells (120). Syn3 acts as a transfer enhancer that
circumvents the need for CAR binding (119).
A comparison of intravesical instillation (single adminis-
tration) of viral IFN gene therapy (Ad-IFN/Syn3, recombi-
nant replication-deficient adenovirus containing human IFN
alpha-2b gene and Syn3) to intravesical IFN showed that IFN
gene therapy resulted in much higher IFN concentrations
(1000-times higher peak level) that were sustained for a much
longer duration (96 hr or longer vs undetectable at 24 hr) in
urothelial tissues (121). This same study further showed that a
second dose of viral gene therapy on day 3 was sufficient to
maintain the IFN level in urine. Another study demonstrated
that intravesical treatment with Ad-IFN/Syn3 for 1 hr on two
consecutive days resulted in more than 40% shrinkage of
murine bladder tumors; the extent of antitumor effect was
correlated with the dose size of Ad-IFN and the IFN
concentration in urine (122). Other replication-deficient
adenovirus-mediated gene therapy targeting p53 (123), bFGF
(124), IL-8 (125) also demonstrated successful gene delivery
and effective inhibition of tumor growth in orthotopic (123)
or subcutaneous (124,125) mouse bladder tumor models.
Another approach is the replication-competent oncolytic
adenovirus, which, through self replication, results in lysis of
tumor cells. CG0070, an oncolytic adenovirus encoding
granulocyte macrophage colony stimulating factor (GM-
CSF), preferentially replicates in retinoblastoma protein-
defective bladder cancer cells and produces GM-CSF that
activates host immune response (126). The tumor selectivity
of CG0070 was indicated by the 100-fold higher replication
and 1000-fold greater cytotoxicity in bladder transitional cell
carcinoma cells compared to normal cells. CG0070 showed
significant activities against orthotopic and subcutaneous
human xenograft bladder tumor model in mice (126), and is
undergoing phase 1 clinical trial in patients with recurrent
bladder cancer after BCG treatment (127).
Vaccinia is a large, double-stranded DNA virus used for
vaccination against smallpox (128). The advantages of
recombinant vaccinia virus (rVV) include application in a
wide range of hosts, rapid infection and efficient expression of
inserted transgenes (112). Early experiments demonstrated
that rVV effectively introduced functional genes into bladder
tumor cells in vitro and in vivo (129). In a syngeneic,
orthotopic mouse bladder tumor model, delivery of p53 gene
using rVV (rVV-TK-53) resulted in 33% survival on day 70,
whereas the delivery using phosphate buffer or empty vector
showed no survival benefits (112).
Several phase I trials demonstrated that intravesical gene
therapy can be safely administered to bladder cancer patients;
no dose-limiting toxicity was observed for Dryvax vaccinia viral
vectors (no therapeutic gene, 4 patients) (130) and adenoviral
vector containing wild-type p53 gene with a gene-transfer
enhancer (Big CHAP, 12 patients, single treatment) (131). The
latter treatment resulted in the induction of RNA and protein
levels of p21/WAF1 (downstream target of p53) in patient
tumors, and the expression of vector DNA uniformly through-
out the urothelium and submucosal tumors, indicating success-
ful transgene expression. A third study in 13 patients receiving
repeated doses of adenoviral vector-mediated p53 (Ad5CMV-
p53) on a 28-day cycle also showed good tolerability at the
highest dose of 1012 viral particles (132). Specific transgene
expression was observed in 2 of 7 patients that yielded biopsy
samples. Two recently initiated studies are evaluating
intravesical Ad-IFN/Syn3 (133) and Ad-GM-CSF (127) in
patients with recurrent, BCG-refractory bladder cancer.
In intravesical viral gene delivery, the primary safety
concern is the inadvertent absorption of the vectors into the
systemic circulation, as viral vectors may produce excessive
immune response or insertional mutagenesis in host cells. In
comparison, nonviral vectors (e.g., Lipoplexes) have the
advantages of simple preparation, low-cost, easy manufactur-
ing, low immunogenicity, and can carry larger size genes
(134). In mice bearing established orthotopic bladder tumors,
intravesical treatments of IL-2 gene therapy (delivered in
cationic liposomal formulations, 6 treatments given every
other day) resulted in higher survival rate, compared to the
reporter gene control (40% versus 0% on day 60) (135).
Similarly, IL-12 gene therapy (delivered in cationic liposomes,
6 treatments given every 3 days) was equally effective as high
dose BCG (400 μg) in the same mouse model, and both
treatments were significantly better compared to the reporter
gene control (30% survival on day 60 vs 0%). Interestingly,
IL-12 gene therapy was more efficacious than BCG in the
surviving mice that were again implanted with orthotopic
bladder tumors (100% vs 0% survival on day 60 after the
reimplantation of tumor cells), suggesting more durable
benefits of IL-12 gene therapy (136). Lipid-based gene
vectors have undergone clinical evaluation in other cancer
types, with good safety records (137–143).
Other experimental approaches. Small interfering RNA
(siRNA) is emerging as novel cancer therapeutic agents (144–
146). siRNA silences the expression of the targeted gene in a
sequence-specific manner on the mRNA level. Treatment
with survivin- or telomerase-targeted siRNA down-regulated
the expression of the corresponding protein and suppressed
the growth of bladder tumor cells (147–149). Instillation of
siRNA/cationic liposomes targeting polo-like kinase-1 or
PLK-1, a biomarker of poor prognosis in a murine orthotopic
bladder cancer model, resulted in significant inhibition of
PLK-1 expression and lowering the PLK-1 protein level in
bladder tissues, in a time- and dose-dependent manner (150).
Another emerging experimental approach, still in pre-
clinical evaluation, is using chemosensitizer to enhance the
activity of agents with demonstrated clinical benefits. In
cultured cells, meglumine-modified eicosapentaenoic acid,
an omega-3 fatty acid, enhances the cellular uptake and
activity of epirubicin and MMC (151). Our laboratory has
shown that suramin, when given at non-cytotoxic doses,
enhances the activity of MMC against human transitional cell
RT4 xenograft tumor in mice (152). Suramin is a polyanion
with over 20 molecular targets, including growth factors and
proteins involved in signaling pathways important to cell cycle
check points (153).
PART V. PERSPECTIVES
Because of the unique anatomical and physiological
properties of the urinary bladder, including easy access for
1505Intravesical Treatments of Bladder Cancer: Review
instilling treatment and limited systemic absorption of the
instilled agent, delivery of effective concentrations of thera-
peutics to bladder tumors during intravesical therapy is more
readily accomplished compared to tumors located in systemic
organs (e.g., lungs). From this perspective, treatment of
bladder cancer bears similarity to treating tumor cells under
in vitro conditions. Hence, disease eradication or cures are
real possibilities and should be the goal of future translational
research. In addition, as shown in our work on intravesical
MMC therapy, the computational drug transport models
enable the prediction of drug concentrations in different
parts of the bladder in vivo and, together with the pharma-
codynamic data in human bladder tumors, can be used to
predict the outcomes of different treatment conditions (e.g.,
dose, concentration, dwell time) and thereby enable the
selection of optimal treatment conditions. From the stand-
point of clinical therapy development, such computational
approaches enable the projection of the anticipated benefits,
including the margins of errors, of the experimental treat-
ments and consequently the selection of appropriate patient
sample sizes for detecting the desired statistical significance.
Such quantitative approaches have the potential of improving
the success rate of the clinical development of new treat-
ments, which currently stands at <6% for cancer therapeutics
(154). Finally, additional lessons learned from the use of
intravesical therapy may improve the utility of other intra-
cavity or regional therapies such as intraperitoneal treatment
of peritoneal cancers or intrathecal treatment of brain cancer.
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